Computational Neurogenomics Laboratory

At the Computational Neurogenomics Laboratory, we work at the intersection of human genetics, data science, digital biomarkers, and brain health. Our research focuses on understanding the genetic and molecular foundations of complex brain-related traits and diseases, with Parkinson's disease (PD) as our primary focus, and extending to sleep disorders, dementia, depression, chronic pain, and self-harm behaviours.

We build world-leading research resources by integrating genomics, neuroimaging, wearable-derived digital biomarkers, and electronic health data to accelerate discoveries in disease prediction, progression, and personalised care. Our methodological toolkit spans genome-wide association studies (GWAS), polygenic risk score development, Mendelian randomisation, and machine learning applied to large biobanks.

We lead major national and international initiatives including the Australian Parkinson's Genetics Study (APGS) — Australia's largest PD genetics cohort with over 21,000 participants — and collaborate globally through the Global Parkinson's Genetics Program (GP2), the Psychiatric Genomics Consortium (PGC), and the ENIGMA Consortium, where we co-chair the Suicidal Thoughts and Behaviours Working Group, coordinating neuroimaging data from over 70 cohorts worldwide.

Our work combines big data analysis, statistical genomics, and translational science to uncover the biological drivers of clinical heterogeneity and develop real-world tools to monitor and predict disease progression.

• Rebecca L Cooper Medical Research Foundation, Australia
• National Health and Medical Research Council, Australia
• Medical Research Future Fund, Australia
• The Michael J. Fox Foundation for Parkinson’s Research, USA
• Shake It Up Australia Foundation, Australia
• IMPACT Philanthropy Funding, Perpetual Ltd, Australia
• National Institute of Mental Health, USA
• American Parkinson’s Disease Association, USA
• Alzheimer’s Association, USA